Purple Biotech
PPBT
8 hedge funds and large institutions have $134K invested in Purple Biotech in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
15% less capital invested
Capital invested by funds: $157K → $134K (-$23K)
20% less funds holding
Funds holding: 10 → 8 (-2)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$36.1K |
| 2 |
VF
Virtu Financial
New York
|
+$19.3K |
| 3 |
KWM
Kingsview Wealth Management
Grants Pass,
Oregon
|
+$14.4K |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$2.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$101K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$26K |
| 3 |
MC
Menta Capital
San Francisco,
California
|
-$14.4K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$13K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $47K | +$19.3K | +8 | +73% |
|
|
2
Morgan Stanley
New York
| $39K | +$36.1K | +15 | +1,500% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $14K | -$101K | -42 | -88% |
|
|
KWM
4
Kingsview Wealth Management
Grants Pass,
Oregon
| $14K | +$14.4K | +6 | New |
|
|
MC
5
Menta Capital
San Francisco,
California
| $13K | -$14.4K | -6 | -50% |
|
6
UBS Group
Zurich,
Switzerland
| $3K | -$2.41K | -1 | -50% |
|
|
BAM
7
Bruderman Asset Management
Locust Valley,
New York
| $2K | – | – | – |
|
|
ASN
8
Advisory Services Network
Atlanta,
Georgia
| $2K | +$2.41K | +1 | New |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$26K | -19 | Closed |
|
|
SM
10
Sabby Management
Miami Beach,
Florida
| – | -$13K | -10 | Closed |
|
|
TSS
11
Two Sigma Securities
New York
| – | -$12K | -9 | Closed |
|
12
Wells Fargo
San Francisco,
California
| – | -$7K | -5 | Closed |
|
PPBT Hedge Fund Activity: Q1 2019 in Review
8 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q1 2019, worth a combined $134K — down 15% from $157K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PPBT and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Morgan Stanley, adding an estimated $36.1K. The largest seller was Susquehanna International Group, cutting an estimated $101K.
- 8 institutional investors held Purple Biotech (PPBT) as of Q1 2019, down from 10 in Q4 2018.
- Funds reported $134K of Purple Biotech stock for Q1 2019, down 15% quarter-over-quarter.
- 2 funds opened new Purple Biotech positions in Q1 2019 and 4 closed out, a net change of -2 holders.
- The largest Purple Biotech buyer in Q1 2019 was Morgan Stanley, an estimated $36.1K added.
- The largest Purple Biotech seller in Q1 2019 was Susquehanna International Group, an estimated $101K sold.
Based on aggregated 13F filings for Q1 2019.